Neon Therapeutics (NASDAQ:NTGN) has filed a Clinical Trial Authorization (CTA) with the Dutch Health Authority for the evaluation of NEO-PTC-01 in patients with metastatic melanoma who are refractory to checkpoint inhibitors.
NEO-PTC-01 is a personal neoantigen-targeted T cell therapy candidate derived from patients’ peripheral blood mononuclear cells.
The company plans to initiate a Phase 1 dose escalation trial in metastatic melanoma in collaboration with the Netherlands Cancer Institute in H1 2020.
Shares are up 3% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.